Allogene Therapeutics, Inc. $ALLO Position Boosted by DAFNA Capital Management LLC

DAFNA Capital Management LLC grew its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 11.3% in the 1st quarter, HoldingsChannel.com reports. The firm owned 1,380,118 shares of the company’s stock after purchasing an additional 140,000 shares during the period. DAFNA Capital Management LLC’s holdings in Allogene Therapeutics were worth $2,015,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Caption Management LLC bought a new position in shares of Allogene Therapeutics during the 4th quarter valued at about $32,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Allogene Therapeutics during the 1st quarter valued at about $28,000. Brooklyn Investment Group bought a new position in shares of Allogene Therapeutics during the 1st quarter valued at about $45,000. Graham Capital Management L.P. bought a new position in shares of Allogene Therapeutics during the 4th quarter valued at about $89,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Allogene Therapeutics during the 1st quarter valued at about $64,000. Institutional investors own 83.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ALLO. Citizens Jmp lowered shares of Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 14th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Wednesday, May 14th. Piper Sandler decreased their target price on shares of Allogene Therapeutics from $9.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th. JMP Securities reiterated a “market perform” rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Allogene Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.44.

Allogene Therapeutics Price Performance

NASDAQ ALLO opened at $1.13 on Friday. The company has a 50 day simple moving average of $1.20 and a 200-day simple moving average of $1.42. The firm has a market capitalization of $250.72 million, a price-to-earnings ratio of -1.02 and a beta of 0.35. Allogene Therapeutics, Inc. has a 52-week low of $0.86 and a 52-week high of $3.78.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. On average, analysts predict that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).